A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Patients With Chemotherapy-Induced Thrombocytopenia

In brief

The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

Key facts

Study ID

NCT07286032

Run by

Jiangsu HengRui Medicine Co., Ltd.

People needed

150

Starts

2026-04-16

Expected to finish

2029-06-01

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female gender, age ≥18 years at screening.
• Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma [NSCLC], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer).
• Receiving platinum- and/or gemcitabine-containing chemotherapy regimens on 21-day treatment cycles.
• Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
• Life expectancy ≥6 months.
• Signed ICF for voluntary participation in the study and good compliance.

You may not qualify if…

• Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).
• Hematologic malignancies.
• Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months prior to Study Day 1.
• Untreated brain metastases; or with leptomeningeal metastasis.
• Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).
• Severe cardiovascular disorders or interventions within 6 months
• Have arterial/venous thrombosis within 6 months
• Known bleeding disorders, platelet dysfunction
• Severe haemorrhage during screening
• Acute or uncontrolled hepatitis B\&C infection
• Human immunodeficiency virus (HIV) infection.

Where it is running

• Mid-Florida Hematology & Oncology Centers, P.A. — Orange City, Florida, United States (enrolling)
• AdventHealth Hematology and Oncology Denver Cypress Hematology and Oncology — Denver, Colorado, United States
• Oncology & Hematology Associates of West Broward — Coral Springs, Florida, United States
• Cancer and Blood Specialty Clinic — Los Alamitos, California, United States
• Springfield Clinic — Springfield, Illinois, United States
• Morristown Medical Center — Morristown, New Jersey, United States
• New York Cancer and Blood Specialists One Oncology — Shirley, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.